U n c o r r e c t e d A u t h o r P r o o f Translational Science of Rare Diseases xx (20xx) x-xx Abstract. Lysosomal Storage Disorders (LSDs) comprise a group of disorders causing defects at the organelle and sub-7 organelle level with a wide range of pathophysiologies and clinical consequences. Signs and symptoms of LSDs involve 8 multiple organ systems. The main pathological mechanism of most LSDs was previously thought to be cytotoxic effects of 9 a specific storage substance secondary to functional impairment or insufficient lysosomal enzymes. Other pathophysiologic 10 mechanisms of LSDs have been discovered such as dysfunction of cell signaling, disturbance of cell homeostasis, inflamma-11 tory process and dysfunction of autophagy. The goal of treatment is to balance equilibrium of the enzyme and the accumulated 12 substance. Replacing deficient enzyme through exogenous enzyme replacement therapy (ERT) or stem cell transplantation 13 has been the main method of treatment for several years. The ability of ERT to alleviate neurologic symptoms is limited 14 owing to the inability of the exogenous enzyme to cross the blood-brain barrier. The benefit of stem cell transplantation on 15 neurologic symptoms has been demonstrated for Hurler syndrome, but it is not clear for most LSDs. Other strategies, such 16 as gene therapy, have been under development to overcome this limitation and provide a better outcome. Early treatment or 17 pre-symptomatic treatment could also slow disease progression and improve prognosis. The scope of this article is to review 18 current and new therapeutic strategies as well as disease non-specific management. 19 Keywords: Lysosomal storage disorders, management 20 20 Lysosomal storage disorders (LSDs) are a group of inherited inborn errors of metabolism (IEM), 21 currently including over 70 disorders. More than two-thirds of LSDs are neuropathic LSDs in which 22 the main clinical symptom is neurodegeneration [1-3].
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but by other mechanisms such as autophagy and inflammation. Therefore, ERT may or may not 280 affect symptoms resulting from these pathogenic factors.
281
• ERT is a feasible strategy only for enzymes that are soluble, not for those that are membrane-bound.
282
• Treatment is lifelong and requires administration weekly to monthly; some ERTs require more 283 than 2 to 5 hours of infusion time.
284
• Infusion-associated reactions.
285
• Immunogenicity.
286
• Cost.
287
Limitations and strategies to overcome the limitations of ERTs 
308
• Postponing an infusion should be considered in patients with acute infection, fever, or respiratory 309 illness at the time of ERT, as they may be at risk of severe hypersensitivity reactions [17] .
310
• For patients who have a history of IARs, many approaches may prevent future IARs, including 311 adding premedication, adding post-infusion antihistamine, and modifying the infusion protocol 312 (such as decreasing the initial infusion rate to 25% to 50% of the recommended rate and slowing 313 the ramping regimen during the first 1 to 2 hours of infusion).
314

IAR: Practical Management
315
Management of IARs should be based on the severity of the reactions.
316
• For mild to moderate reactions, treatment includes slowing or temporary interruption of the infu-317 sion (such as, reducing the infusion rate to 50% until the symptoms resolve, then ramping the 318 infusion rate to the last tolerated rate). For mild reactions, treatment may also include administering 319 additional antihistamines, antipyretics, and/or steroids.
320
• For severe and anaphylaxis reactions, treatment includes immediately discontinuing the infusion, 
338
In general, the severity of pathological variants is related to levels of enzyme production. Patients with 339 2 null mutations usually cannot produce endogenous enzyme (CRIM-negative) and are at higher risk to 340 develop a destructive immune response to ERT; their immune system recognizes exogenous enzymes 341 as foreign and develops high and sustained ADA levels that lead to poor clinical response to ERT.
342
On the other hand, the immune system of CRIM-positive patients is exposed to residual endogenous The current best strategy to alleviate the effect of immune intolerance is immune tolerance 350 introduction (ITI), the goal of which is to prevent or suppress ADAs. Ideally ITI should be started 351 before initiation of ERT since it is easier to eradicate naïve antigen-specific T and B cells than memory • Cysteamine is a good example of a drug in this class. This drug is used to treat cystinosis. 
